1. GPCR/G Protein
  2. LPL Receptor

LPL Receptor

LPL Receptor (Lysophospholipid Receptor) group are members of the G protein-coupled receptor family of integral membrane proteins that are important for lipid signaling. In humans, there are eight LPL receptors, each encoded by a separate gene. These LPL receptor genes are also sometimes referred to as "Edg". LPL receptor ligands bind to and activate their cognate receptors located in the cell membrane. Depending on which ligand, receptor, and cell type is involved, the activated receptor can have a range of effects on the cell. These include primary effects of inhibition of adenylyl cyclase and release of calcium from the endoplasmic reticulum, as well as secondary effects of preventingapoptosis and increasing cell proliferation. Type: LPAR1, LPAR2, LPAR3, LPAR4, LPAR5, LPAR6, S1PR1, S1PR2, S1PR3, S1PR4, S1PR5.

LPL Receptor Related Products (27):

Cat. No. Product Name Effect Purity
  • HY-12005
    Fingolimod hydrochloride Modulator 99.76%
    Fingolimod hydrochloride is a sphingosine 1-phosphate (S1P) antagonist with an IC50 of 0.033 nM in K562 and NK cells.
  • HY-13285
    Ki16425 Antagonist 98.67%
    Ki16425 is a subtype-selective, competitive antagonist of the EDG-family receptors, LPA1 and LPA3 with Kis of 0.34 μM and 0.93 μM, respectively.
  • HY-12355
    Siponimod Agonist 98.61%
    Siponimod (BAF-312) is a potent and selective sphingosine-1-phosphate (S1P) receptor modulator. It is selective for S1P1 and S1P5 receptors over S1P2, S1P3, and S1P4 (EC50s of 0.39, 0.98, >10,000, >1,000, and 750 nM, respectively.)
  • HY-15277
    AM966 Antagonist 98.75%
    AM966 is a high affinity, selective, oral LPA1-antagonist, inhibits LPA-stimulated intracellular calcium release (IC50=17 nM).
  • HY-12288
    Ozanimod Agonist 99.81%
    Ozanimod is a potent and selective S1P1 and S1P5 receptor agonist with EC50s of 410±160 pM and 11±4.3 nM in [35S]-GTPγS binding, respectively.
  • HY-12685
    Ceralifimod Agonist
    Ceralifimod is selective, high potent agonist for sphingosine 1-phosphate receptors 1 and 5, with EC50s of 27.3, 334 pM for human S1P receptor 1 and 5, respectively.
  • HY-19511
    GSK2018682 Agonist 98.23%
    GSK2018682 is an agonist for S1P1 and S1P5 receptor with pEC50s of 7.7 and 7.2, respectively, and has no agonist activity towards human S1P2, S1P3, or S1P4. GSK2018682 is used in the research of multiple sclerosis.
  • HY-18076
    LPA1 antagonist 1 Antagonist
    LPA1 antagonist 1 is a highly selective Lysophosphatidic Acid receptor-1 (LPA1) antagonist with an IC50 of 25 nM.
  • HY-100619
    BMS-986020 Antagonist 98.02%
    BMS-986020 is an LPA1 antagonist.
  • HY-11063
    Fingolimod Antagonist 99.95%
    Fingolimod is a sphingosine 1-phosphate (S1P) antagonist with IC50 of 0.033 nM in K562 and NK cells.
  • HY-19736
    TY-52156 Antagonist 99.68%
    TY-52156 is a potent S1P3 receptor antagonist in a competitive manner, and the Ki value is estimated to be 110 nM for S1P3 receptor.
  • HY-18075
    LPA2 antagonist 1 Inhibitor 98.85%
    LPA2 antagonist 1 is a LPA2 antagonist with an IC50 of 17 nM.
  • HY-16039
    AM095 Antagonist 98.14%
    AM095 is a selective LPA1 receptor antagonist. The IC50 for AM095 antagonism of LPA-induced calcium flux of human or mouse LPA1-transfected CHO cells is 0.025 and 0.023 μM, respectively.
  • HY-16040
    AM095 free acid Inhibitor 99.28%
    AM095 (free acid) is a potent LPA1 receptor antagonist with IC50 values of 0.98 and 0.73 μM for recombinant human or mouse LPA1 respectively.
  • HY-12789
    Etrasimod Antagonist 99.64%
    Etrasimod (APD334) is a potent, selective and orally available antagonist of the sphingosine-1-phosphate-1 (S1P1) receptor with an IC50 value of 1.88 nM in CHO cells.
  • HY-17606
    Cenerimod Agonist 98.43%
    Cenerimod (ACT-334441) is a potent and orally available sphingosine 1-phosphate 1 receptor (S1P1) agonist extracted from patent WO 2016184939 A1 and WO 2011007324 A1, example 1, with an EC50 of 2.7 nM.
  • HY-13447A
    PF429242 dihydrochloride Inhibitor 98.76%
    PF429242 dihydrochloride is a reversible and competitive S1P inhibitor with an IC50 of 175 nM.
  • HY-10569
    Ponesimod Agonist 99.53%
    Ponesimod(ACT-128800) is an orally active, selective sphingosine-1-phosphate receptor 1 (S1P1) immunomodulator.
  • HY-101265
    S1p receptor agonist 1 Agonist 98.28%
    S1p receptor agonist 1 is an S1P receptor agonist extracted from patent WO 2015039587 A1, compound example 2.
  • HY-16734A
    Amiselimod hydrochloride Agonist 98.91%
    Amiselimod hydrochloride is a novel sphingosine 1-phosphate receptor-1 (S1P1) modulator, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators.